Peptide Knowledge Base · Cognition
Cerebrolysin: what it is, what the evidence says, and its real status
A porcine-derived neurotrophic peptide preparation with a long clinical heritage in stroke and dementia abroad, the most-evidenced nootropic peptide.
Short version: the most-studied peptide in the nootropic conversation, 70-plus human studies and decades of clinical use abroad in stroke and dementia. Not US-approved, so for us it is education and waitlist, led with the evidence.
Can you actually get it?
Plain-English verdict: Waitlist / education.
Regulatory status: Used clinically abroad · not US-approved · Education only.
Not available to prescribe in the US. Cerebrolysin is used clinically in other countries for stroke and dementia, with a large human-study base, but it is not FDA-approved and not compoundable here. Education and demand-capture only.
How does Cerebrolysin work?
A standardized mix of low-molecular-weight neuropeptides and amino acids proposed to mimic neurotrophic-factor activity supporting neuronal survival and repair.
What it does — and what it does not do
What it does: Studied extensively abroad for recovery after stroke and in dementia; the evidence-forward entry in the cognition cluster.
What it does not do: It is not US-approved or available here, and trial quality across the literature is mixed.
How honest is the evidence?
Evidence grade B — 70+ human studies abroad; heterogeneous quality; not US-approved. Read our grading methodology for what each grade means.
What we still don't know: Trial quality is heterogeneous; US regulatory path and standardized benefit are unsettled.
WADA status: Not prohibited.
How it is taken
What the literature reports for clinical use abroad: IM or IV courses. Educational only, no dose figures.
Who should not take it
Not US-approved; clinician-managed where used; discuss seizure history and allergy. Not characterized for general use here.
Sources
Cerebrolysin stroke/dementia trial literature (used clinically abroad; quality varies)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.